Atezolizumab/nivolumabType 1 diabetes mellitus: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1688卷 / 1期

关键词：

D O I：

10.1007/s40278-018-41670-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：35 / 35

相关论文

共 50 条

[1] NivolumabType 1 diabetes mellitus and adrenal insufficiency: 2 case reports
Reactions Weekly, 2020, 1785 (1) : 396 - 396
[2] NivolumabType 1 diabetes mellitus, hypothyroidism and thyrotoxicosis: 2 case reports
Reactions Weekly, 2020, 1795 (1) : 207 - 207
[3] Atezolizumab/Ipilimumab/NivolumabType 1 diabetes mellitus and isolated adrenocorticotropic hormone deficiency: 3 case reports
Reactions Weekly, 2024, 2021 (1) : 91 - 91
[4] Ipilimumab/nivolumabType 1 diabetes mellitus, pancreatic injury and autoimmune thyroiditis: 2 case reports
Reactions Weekly, 2020, 1788 (1) : 136 - 136
[5] NivolumabType 1 diabetes mellitus: case report
Reactions Weekly, 2020, 1787 (1) : 398 - 398
[6] NivolumabType 1 diabetes mellitus: case report
Reactions Weekly, 2020, 1792 (1) : 177 - 177
[7] NivolumabType-1 diabetes mellitus: case report
Reactions Weekly, 2021, 1837 (1) : 532 - 532
[8] Ipilimumab/nivolumabType 1 diabetes mellitus: case report
Reactions Weekly, 2024, 2037 (1) : 221 - 221
[9] NivolumabType-1-diabetes-mellitus: case report
Reactions Weekly, 2020, 1809 (1) : 191 - 191
[10] NivolumabType-1 diabetes mellitus: case report
Reactions Weekly, 2019, 1753 (1) : 261 - 261

← 1 2 3 4 5 →